Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

CD133 in Breast Cancer Cells: More than a Stem Cell Marker.

Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V.

J Oncol. 2019 Sep 16;2019:7512632. doi: 10.1155/2019/7512632. eCollection 2019. Review.

2.

Dynamical Generation of Elementary Fermion Mass: First Lattice Evidence.

Capitani S, Dimopoulos P, Frezzotti R, Garofalo M, Kostrzewa B, Pittler F, Rossi GC, Urbach C.

Phys Rev Lett. 2019 Aug 9;123(6):061802. doi: 10.1103/PhysRevLett.123.061802.

PMID:
31491142
3.

Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.

Bertagnolo V, Grassilli S, Volinia S, Al-Qassab Y, Brugnoli F, Vezzali F, Lambertini E, Palomba M, Piubello Q, Orvieto E, Natali C, Piva R, Croce CM, Capitani S.

Mol Carcinog. 2019 May;58(5):708-721. doi: 10.1002/mc.22964. Epub 2019 Jan 16.

4.

Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.

Bertacchini J, Mediani L, Beretti F, Guida M, Ghalali A, Brugnoli F, Bertagnolo V, Petricoin E, Poti F, Arioli J, Anselmi L, Bari A, McCubrey J, Martelli AM, Cocco L, Capitani S, Marmiroli S.

J Cell Physiol. 2019 Jul;234(7):11188-11199. doi: 10.1002/jcp.27768. Epub 2018 Nov 22.

PMID:
30565691
5.

Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.

Al-Qassab Y, Grassilli S, Brugnoli F, Vezzali F, Capitani S, Bertagnolo V.

BMC Cancer. 2018 Nov 29;18(1):1194. doi: 10.1186/s12885-018-5038-6.

6.

Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells.

Volinia S, Bertagnolo V, Grassilli S, Brugnoli F, Manfrini M, Galasso M, Scatena C, Mazzanti CM, Lessi F, Naccarato G, Caligo A, Bianchini E, Piubello Q, Orvieto E, Rugge M, Natali C, Reale D, Vecchione A, Warner S, Croce CM, Capitani S.

Oncotarget. 2018 May 4;9(34):23543-23553. doi: 10.18632/oncotarget.25261. eCollection 2018 May 4.

7.

Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise.

Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17238-17254. doi: 10.18632/oncotarget.24428. eCollection 2018 Mar 30. Review.

8.

Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases.

Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17220-17237. doi: 10.18632/oncotarget.24991. eCollection 2018 Mar 30. Review.

9.

Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.

Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, Neri LM.

J Cell Physiol. 2018 Oct;233(10):6440-6454. doi: 10.1002/jcp.26539. Epub 2018 Apr 18. Review.

PMID:
29667769
10.

Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome.

Grassilli S, Brugnoli F, Lattanzio R, Marchisio M, Perracchio L, Piantelli M, Bavelloni A, Capitani S, Bertagnolo V.

Mol Oncol. 2018 Jun;12(7):1012-1025. doi: 10.1002/1878-0261.12203. Epub 2018 May 16.

11.

Impact of physical exercise in cancer survivors during and after antineoplastic treatments.

Ferioli M, Zauli G, Martelli AM, Vitale M, McCubrey JA, Ultimo S, Capitani S, Neri LM.

Oncotarget. 2018 Feb 8;9(17):14005-14034. doi: 10.18632/oncotarget.24456. eCollection 2018 Mar 2. Review.

12.

Vav1 is necessary for PU.1 mediated upmodulation of miR-29b in acute myeloid leukaemia-derived cells.

Vezzali F, Grassilli S, Lambertini E, Brugnoli F, Patergnani S, Nika E, Piva R, Pinton P, Capitani S, Bertagnolo V.

J Cell Mol Med. 2018 Jun;22(6):3149-3158. doi: 10.1111/jcmm.13594. Epub 2018 Mar 13.

13.

Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC.

Brugnoli F, Grassilli S, Lanuti P, Marchisio M, Al-Qassab Y, Vezzali F, Capitani S, Bertagnolo V.

BMC Cancer. 2017 Sep 4;17(1):617. doi: 10.1186/s12885-017-3592-y.

14.

Risk factors associated with relapse of eyelid basal cell carcinoma: results from a retrospective study of 142 patients.

Fatigato G, Capitani S, Milani D, Grassilli S, Alameen AA, Candiani M, Riberti C, Galasso M, Previati M.

Eur J Dermatol. 2017 Aug 1;27(4):363-368. doi: 10.1684/ejd.2017.3026.

PMID:
28524055
15.

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.

Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.

16.

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.

Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2016 Nov 29;7(48):79842-79853. doi: 10.18632/oncotarget.13035.

17.

Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.

Alameen AA, Simioni C, Martelli AM, Zauli G, Ultimo S, McCubrey JA, Gonelli A, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2016 Aug 23;7(34):55690-55703. doi: 10.18632/oncotarget.10984.

18.

A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.

Grassilli S, Nika E, Lambertini E, Brugnoli F, Piva R, Capitani S, Bertagnolo V.

Cell Oncol (Dordr). 2016 Oct;39(5):483-489. Epub 2016 Aug 1.

PMID:
27480083
19.

Blink reflex in subjects with different hypnotizability: New findings for an old debate.

Santarcangelo EL, Briscese L, Capitani S, Orsini P, Varanini M, Rossi B, Carboncini MC.

Physiol Behav. 2016 Sep 1;163:288-293. doi: 10.1016/j.physbeh.2016.05.021. Epub 2016 May 13.

PMID:
27184234
20.

PLC-β2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential.

Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V.

Mol Carcinog. 2016 Dec;55(12):2210-2221. doi: 10.1002/mc.22462. Epub 2016 Jan 19.

PMID:
26785288
21.

Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.

Mediani L, Gibellini F, Bertacchini J, Frasson C, Bosco R, Accordi B, Basso G, Bonora M, Calabrò ML, Mattiolo A, Sgarbi G, Baracca A, Pinton P, Riva G, Rampazzo E, Petrizza L, Prodi L, Milani D, Luppi M, Potenza L, De Pol A, Cocco L, Capitani S, Marmiroli S.

Oncotarget. 2016 Feb 2;7(5):5521-37. doi: 10.18632/oncotarget.6315.

22.

Inhibition of Ras-mediated signaling pathways in CML stem cells.

Bertacchini J, Ketabchi N, Mediani L, Capitani S, Marmiroli S, Saki N.

Cell Oncol (Dordr). 2015 Dec;38(6):407-18. doi: 10.1007/s13402-015-0248-2. Epub 2015 Oct 12. Review.

PMID:
26458816
23.

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Jul 10;6(19):17147-60.

24.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

25.

Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N.

Cell Mol Life Sci. 2015 Jun;72(12):2337-47. doi: 10.1007/s00018-015-1867-5. Epub 2015 Feb 25. Review.

PMID:
25712020
26.

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.

Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM.

Oncotarget. 2014 Oct 30;5(20):10034-47.

27.

Microparticle-loaded neonatal porcine Sertoli cells for cell-based therapeutic and drug delivery system.

Giovagnoli S, Mancuso F, Vannini S, Calvitti M, Piroddi M, Pietrella D, Arato I, Falabella G, Galli F, Moretti M, Neri LM, Bodo M, Capitani S, Cameron DF, Ricci M, Luca G, Calafiore R.

J Control Release. 2014 Oct 28;192:249-61. doi: 10.1016/j.jconrel.2014.08.001. Epub 2014 Aug 8.

PMID:
25111130
28.

hnRNP K in PU.1-containing complexes recruited at the CD11b promoter: a distinct role in modulating granulocytic and monocytic differentiation of AML-derived cells.

Nika E, Brugnoli F, Piazzi M, Lambertini E, Grassilli S, Bavelloni A, Piva R, Capitani S, Bertagnolo V.

Biochem J. 2014 Oct 1;463(1):115-22. doi: 10.1042/BJ20140358.

PMID:
25005557
29.

High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process.

Grassilli S, Brugnoli F, Lattanzio R, Rossi C, Perracchio L, Mottolese M, Marchisio M, Palomba M, Nika E, Natali PG, Piantelli M, Capitani S, Bertagnolo V.

Oncotarget. 2014 Jun 30;5(12):4320-36.

30.

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness.

Brugnoli F, Grassilli S, Piazzi M, Palomba M, Nika E, Bavelloni A, Capitani S, Bertagnolo V.

Mol Cancer. 2013 Dec 13;12:165. doi: 10.1186/1476-4598-12-165.

31.

The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.

Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2013 Sep;4(9):1496-506.

32.

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, Capitani S.

Leukemia. 2014 Apr;28(4):739-48. doi: 10.1038/leu.2013.226. Epub 2013 Jul 29.

PMID:
23892718
33.

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM.

Leukemia. 2012 Nov;26(11):2336-42. doi: 10.1038/leu.2012.136. Epub 2012 May 22.

PMID:
22614243
34.

Basal and post-ischemic vascular compliance in children/adolescents born small for gestational age.

Strambi M, Messa G, Berni S, Capitani S, Pammolli A, Iacoponi F, Censurato C, Magne Tene C, Fiorica A, Vittoria A.

Pediatr Nephrol. 2012 Sep;27(9):1541-6. doi: 10.1007/s00467-012-2168-y. Epub 2012 May 10.

35.

Vav1 in differentiation of tumoral promyelocytes.

Bertagnolo V, Brugnoli F, Grassilli S, Nika E, Capitani S.

Cell Signal. 2012 Mar;24(3):612-20. doi: 10.1016/j.cellsig.2011.11.017. Epub 2011 Nov 28. Review.

PMID:
22133616
36.

Nuclear proteome analysis reveals a role of Vav1 in modulating RNA processing during maturation of tumoral promyelocytes.

Bertagnolo V, Grassilli S, Petretto A, Lambertini E, Astati L, Bruschi M, Brugnoli F, Nika E, Candiano G, Piva R, Capitani S.

J Proteomics. 2011 Dec 21;75(2):398-409. doi: 10.1016/j.jprot.2011.08.005. Epub 2011 Aug 11.

PMID:
21856460
37.

Vav1 is a crucial molecule in monocytic/macrophagic differentiation of myeloid leukemia-derived cells.

Bertagnolo V, Nika E, Brugnoli F, Bonora M, Grassilli S, Pinton P, Capitani S.

Cell Tissue Res. 2011 Jul;345(1):163-75. doi: 10.1007/s00441-011-1195-5. Epub 2011 Jun 7.

PMID:
21647562
38.

Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.

Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P.

Invest New Drugs. 2012 Feb;30(1):417-22. doi: 10.1007/s10637-010-9564-6. Epub 2010 Oct 16.

PMID:
20953816
39.

Distribution of α- and δ-tocopherols in seminal plasma and sperm fractions of men with normal and abnormal semen parameters.

Moretti E, Castellini C, Mourvaki E, Capitani S, Geminiani M, Renieri T, Collodel G.

J Androl. 2011 May-Jun;32(3):232-9. doi: 10.2164/jandrol.109.009936. Epub 2010 Oct 7.

PMID:
20930194
40.

Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.

Buontempo F, Ersahin T, Missiroli S, Senturk S, Etro D, Ozturk M, Capitani S, Cetin-Atalay R, Neri ML.

Invest New Drugs. 2011 Dec;29(6):1303-13. doi: 10.1007/s10637-010-9486-3. Epub 2010 Jul 14.

PMID:
20628892
41.

Early identification of the risk for free radical-related diseases in preterm newborns.

Perrone S, Tataranno ML, Negro S, Longini M, Marzocchi B, Proietti F, Iacoponi F, Capitani S, Buonocore G.

Early Hum Dev. 2010 Apr;86(4):241-4. doi: 10.1016/j.earlhumdev.2010.03.008. Epub 2010 May 13.

PMID:
20466493
42.

Phytothermotherapy: a possible complementary therapy for fibromyalgia patients.

Fioravanti A, Bellisai B, Capitani S, Manica P, Paolazzi G, Galeazzi M.

Clin Exp Rheumatol. 2009 Sep-Oct;27(5 Suppl 56):S29-32.

PMID:
20074436
43.

Mass spectrometry-based identification of Y745 of Vav1 as a tyrosine residue crucial in maturation of acute promyelocytic leukemia-derived cells.

Bertagnolo V, Grassilli S, D'Aguanno S, Brugnoli F, Bavelloni A, Faenza I, Nika E, Urbani A, Cocco L, Capitani S.

J Proteome Res. 2010 Feb 5;9(2):752-60. doi: 10.1021/pr900581y.

PMID:
20028078
44.

Even routine painful procedures can be harmful for the newborn.

Bellieni CV, Iantorno L, Perrone S, Rodriguez A, Longini M, Capitani S, Buonocore G.

Pain. 2009 Dec 15;147(1-3):128-31. doi: 10.1016/j.pain.2009.08.025. Epub 2009 Sep 27.

PMID:
19786323
45.

Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation.

Brugnoli F, Lambertini E, Varin-Blank N, Piva R, Marchisio M, Grassilli S, Miscia S, Capitani S, Bertagnolo V.

Exp Cell Res. 2010 Jan 1;316(1):38-47. doi: 10.1016/j.yexcr.2009.09.004. Epub 2009 Sep 10.

PMID:
19747912
46.

Semen quality of male idiopathic infertile smokers and nonsmokers: an ultrastructural study.

Collodel G, Capitani S, Pammolli A, Giannerini V, Geminiani M, Moretti E.

J Androl. 2010 Mar-Apr;31(2):108-13. doi: 10.2164/jandrol.109.007773. Epub 2009 Sep 10.

47.

Retrospective assessment of potential negative synergistic effects of varicocele and tobacco use on ultrastructural sperm morphology.

Collodel G, Capitani S, Iacoponi F, Federico MG, Pascarelli NA, Moretti E.

Urology. 2009 Oct;74(4):794-9. doi: 10.1016/j.urology.2009.01.078. Epub 2009 Aug 5.

PMID:
19660794
48.

Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3.

Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S, Marchisio M.

Cell Res. 2009 Sep;19(9):1079-89. doi: 10.1038/cr.2009.80. Epub 2009 Jun 30.

PMID:
19564891
49.

Infection by CagA-positive Helicobacter pylori strains may contribute to alter the sperm quality of men with fertility disorders and increase the systemic levels of TNF-alpha.

Collodel G, Moretti E, Campagna MS, Capitani S, Lenzi C, Figura N.

Dig Dis Sci. 2010 Jan;55(1):94-100. doi: 10.1007/s10620-008-0704-1. Epub 2009 Jan 22.

PMID:
19160044
50.

The presence of bacteria species in semen and sperm quality.

Moretti E, Capitani S, Figura N, Pammolli A, Federico MG, Giannerini V, Collodel G.

J Assist Reprod Genet. 2009 Jan;26(1):47-56. doi: 10.1007/s10815-008-9283-5. Epub 2008 Dec 17.

Supplemental Content

Loading ...
Support Center